Fructose drives de novo lipogenesis affecting metabolic health.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing human intervention trials and mechanistic animal studies.
PubMed 36753292 · doi:10.1530/JOE-22-0270
What was done
This narrative review synthesized evidence from human intervention studies administering physiological doses of sugar and mechanistic animal experiments to assess how fructose consumption influences hepatic de novo lipogenesis (DNL) and associated metabolic conditions such as non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes.
What was found
The abstract reports qualitative mechanistic conclusions without quantitative data or effect sizes. It reports that fructose induces hepatic DNL more potently than glucose due to preferential hepatic fructose metabolism and upregulated expression of fructolytic and lipogenic enzymes. The resulting increase in DNL promotes ectopic fat accumulation in the liver and may disrupt beta-cell function, insulin secretion, and insulin sensitivity.
Why it matters
It outlines the metabolic pathways through which dietary fructose uniquely drives liver fat synthesis and insulin resistance compared to other carbohydrates.
Limits
The paper is an unsystematic narrative review with no defined search criteria, risk-of-bias assessment, or pooled quantitative analysis. The abstract reports no numerical results, and conclusions rely heavily on mechanistic animal studies alongside heterogeneous human intervention data.
Cited by
- supports When the liver metabolizes fructose, it stimulates de novo lipogenesis and fat production.